Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / NVCR - Delcath Systems: Cancer-Treatment Device Company With Upcoming Phase 3 Readout

NVCR - Delcath Systems: Cancer-Treatment Device Company With Upcoming Phase 3 Readout

NovoCure Limited
  • Delcath Systems develops drug/device combos to treat liver cancers.
  • The company’s stock is underappreciated due to past clinical failures and a de-listing despite promising clinical data.
  • Delcath updated the trial design for its lead product to address past issues around patient recruitment and toxicity.
  • With approval in Europe and a track record of treatment, Delcath's US trial is de-risked.
  • The investment thesis for Delcath is a binary event centered around an upcoming clinical trial readout in the US for its lead product.

For further details see:

Delcath Systems: Cancer-Treatment Device Company With Upcoming Phase 3 Readout
Stock Information
Company Name: NovoCure Limited
Stock Symbol: NVCR
Market: NASDAQ
Website: novocure.com
Menu
NVCR NVCR Quote NVCR Short NVCR News NVCR Articles NVCR Message Board
Get NVCR Alerts

News, Short Squeeze, Breakout and More Instantly...